Flanigan, K.M. et al. Genetic characterization of a large, historically significant Utah kindred with facioscapulohumeral dystrophy. Neuromuscul. Disord. 11, 525–529 (2001).
Mostacciuolo, M.L. et al. Facioscapulohumeral muscular dystrophy: epidemiological and molecular study in a north-east Italian population sample. Clin. Genet. 75, 550–555 (2009).
Padberg, G.W. Facioscapulohumeral disease. PhD thesis, Leiden University (1982).
Padberg, G.W. et al. Facioscapulohumeral muscular dystrophy in the Dutch population. Muscle Nerve 2, S81–S84 (1995).
van Deutekom, J.C. et al. FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum. Mol. Genet. 2, 2037–2042 (1993).
Wijmenga, C. et al. Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat. Genet. 2, 26–30 (1992).
Pandya, S., King, W.M. & Tawil, R. Facioscapulohumeral dystrophy. Phys. Ther. 88, 105–113 (2008).
Dixit, M. et al. DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, encodes a transcriptional activator of PITX1. Proc. Natl. Acad. Sci. USA 104, 18157–18162 (2007).
Gabriëls, J. et al. Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element. Gene 236, 25–32 (1999).
Lemmers, R.J. et al. A unifying genetic model for facioscapulohumeral muscular dystrophy. Science 329, 1650–1653 (2010).
Bosnakovski, D. et al. An isogenetic myoblast expression screen identifies DUX4-mediated FSHD-associated molecular pathologies. EMBO J. 27, 2766–2779 (2008).
Kowaljow, V. et al. The DUX4 gene at the FSHD1A locus encodes a pro-apoptotic protein. Neuromuscul. Disord. 17, 611–623 (2007).
Snider, L. et al. Facioscapulohumeral dystrophy: incomplete suppression of a retrotransposed gene. PLoS Genet. 6, e1001181 (2010).
Scionti, I. et al. Large-scale population analysis challenges the current criteria for the molecular diagnosis of fascioscapulohumeral muscular dystrophy. Am. J. Hum. Genet. 90, 628–635 (2012).
Jones, T.I. et al. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis. Hum. Mol. Genet. 21, 4419–4430 (2012).
Shay, J.W. & Wright, W.E. Role of telomeres and telomerase in cancer. Semin. Cancer Biol. 21, 349–353 (2011).
Mondoux, M. & Zakian, V.A. Telomere position effect: silencing near the end. in Telomeres (eds. De Lange, T., Lundblad, V. & Blackburn, E.H.) 261–316 (Cold Spring Harbor Laboratory, 2006).
Girton, J.R. & Johansen, K.M. Chromatin structure and the regulation of gene expression: the lessons of PEV in Drosophila. Adv. Genet. 61, 1–43 (2008).
Gottschling, D.E., Aparicio, O.M., Billington, B.L. & Zakian, V.A. Position effect at S. cerevisiae telomeres: reversible repression of Pol II transcription. Cell 63, 751–762 (1990).
Hazelrigg, T., Levis, R. & Rubin, G.M. Transformation of white locus DNA in Drosophila: dosage compensation, zeste interaction, and position effects. Cell 36, 469–481 (1984).
Baur, J.A., Zou, Y., Shay, J.W. & Wright, W.E. Telomere position effect in human cells. Science 292, 2075–2077 (2001).
Gao, Q. et al. Telomeric transgenes are silenced in adult mouse tissues and embryo fibroblasts but are expressed in embryonic stem cells. Stem Cells 25, 3085–3092 (2007).
Koering, C.E. et al. Human telomeric position effect is determined by chromosomal context and telomeric chromatin integrity. EMBO Rep. 3, 1055–1061 (2002).
Pedram, M. et al. Telomere position effect and silencing of transgenes near telomeres in the mouse. Mol. Cell Biol. 26, 1865–1878 (2006).
Lou, Z. et al. Telomere length regulates ISG15 expression in human cells. Aging (Albany, NY) 1, 608–621 (2009).
Ottaviani, A. et al. The D4Z4 macrosatellite repeat acts as a CTCF and A-type lamins-dependent insulator in facio-scapulo-humeral dystrophy. PLoS Genet. 5, e1000394 (2009).
Ottaviani, A., Schluth-Bolard, C., Gilson, E. & Magdinier, F. D4Z4 as a prototype of CTCF and lamins-dependent insulator in human cells. Nucleus 1, 30–36 (2010).
Stadler, G. et al. Establishment of clonal myogenic cell lines from severely affected dystrophic muscles - CDK4 maintains the myogenic population. Skelet. Muscle 1, 12 (2011).
Homma, S. et al. A unique library of myogenic cells from facioscapulohumeral muscular dystrophy subjects and unaffected relatives: family, disease and cell function. Eur. J. Hum. Genet. 20, 404–410 (2012).
Ramirez, R.D. et al. Bypass of telomere-dependent replicative senescence (M1) upon overexpression of Cdk4 in normal human epithelial cells. Oncogene 22, 433–444 (2003).
Gabellini, D., Green, M.R. & Tupler, R. Inappropriate gene activation in FSHD: a repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 110, 339–348 (2002).
Klooster, R. et al. Comprehensive expression analysis of FSHD candidate genes at the mRNA and protein level. Eur. J. Hum. Genet. 17, 1615–1624 (2009).
Rijkers, T. et al. FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary myoblast cultures of FSHD patients. J. Med. Genet. 41, 826–836 (2004).
Hewitt, J.E. et al. Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy. Hum. Mol. Genet. 3, 1287–1295 (1994).
Kawamura-Saito, M. et al. Fusion between CIC and DUX4 up-regulates PEA3 family genes in Ewing-like sarcomas with t(4;19)(q35;q13) translocation. Hum. Mol. Genet. 15, 2125–2137 (2006).
Geng, L.N. et al. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy. Dev. Cell 22, 38–51 (2012).
Luria, S.E. & Delbruck, M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics 28, 491–511 (1943).
Lambert, D. Zero-inflated Poisson regression, with an application to defects in manufacturing. Technometrics 34, 1–14 (1992).
Decary, S. et al. Replicative potential and telomere length in human skeletal muscle: implications for satellite cell-mediated gene therapy. Hum. Gene Ther. 8, 1429–1438 (1997).
Graakjaer, J. et al. The relative lengths of individual telomeres are defined in the zygote and strictly maintained during life. Aging Cell 3, 97–102 (2004).
Jeanclos, E. et al. Telomere length inversely correlates with pulse pressure and is highly familial. Hypertension 36, 195–200 (2000).
Londoño-Vallejo, J.A., DerSarkissian, H., Cazes, L. & Thomas, G. Differences in telomere length between homologous chromosomes in humans. Nucleic Acids Res. 29, 3164–3171 (2001).
Renauld, H. et al. Silent domains are assembled continuously from the telomere and are defined by promoter distance and strength, and by SIR3 dosage. Genes Dev. 7, 1133–1145 (1993).
van der Maarel, S.M., Tawil, R. & Tapscott, S.J. Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence. Trends Mol. Med. 17, 252–258 (2011).
Slotkin, R.K. & Martienssen, R. Transposable elements and the epigenetic regulation of the genome. Nat. Rev. Genet. 8, 272–285 (2007).
Tassin, A. et al. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy? J. Cell Mol. Med. 17, 76–89 (2013).
Zhu, C.H. et al. Cellular senescence in human myoblasts is overcome by human telomerase reverse transcriptase and cyclin-dependent kinase 4: consequences in aging muscle and therapeutic strategies for muscular dystrophies. Aging Cell 6, 515–523 (2007).
O'Gorman, S., Dagenais, N.A., Qian, M. & Marchuk, Y. Protamine-Cre recombinase transgenes efficiently recombine target sequences in the male germ line of mice, but not in embryonic stem cells. Proc. Natl. Acad. Sci. USA 94, 14602–14607 (1997).
Herbert, B.S., Shay, J.W. & Wright, W.E. Analysis of telomeres and telomerase. Curr. Protoc. Cell Biol. 20, 18.6 (2003).
Baayen, R.H., Davidson, D.J. & Bates, D.M. Mixed-effects modeling with crossed random effects for subjects and items. J. Mem. Lang. 59, 390–412 (2008).
MacKay, D.J.C. Information Theory, Inference and Learning Algorithms (Cambridge University Press, 2003).